Vpr-induced DNA double-strand breaks: Molecular mechanism and biological relevance

Current HIV Research

Volumn 7, Issue 2, 2009, Pages 109-113

  Nakai Murakami, Chikako ^a   Minemoto, Yuzuru ^a   Ishizaka, Yukihito ^a  

^a NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

Author keywords

ATM; DNA double strand breaks; HIV 1; Homologous recombination; Non AIDS defining cancers; Vpr

Indexed keywords

2 MORPHOLINO 6 (1 THIANTHRENYL) 4 PYRANONE; ANTIRETROVIRUS AGENT; ATM PROTEIN; ATR PROTEIN; CAFFEINE; VIRUS DNA; VPR PROTEIN; WORTMANNIN; DNA; VPR PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL ACTIVITY; BIOLOGICAL ACTIVITY; CANCER RISK; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; DNA HELIX; DNA STRAND BREAKAGE; HOMOLOGOUS RECOMBINATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; KAPOSI SARCOMA; MOLECULAR MECHANICS; NONHODGKIN LYMPHOMA; NONHUMAN; PROTEIN DNA INTERACTION; PROTEIN FUNCTION; REVIEW; RISK REDUCTION; VIRUS CARCINOGENESIS; VIRUS CELL INTERACTION; DOUBLE STRANDED DNA BREAK; METABOLISM;

DNA; DNA BREAKS, DOUBLE-STRANDED; HUMANS; VPR GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS;

EID: 64749093893     PISSN: 1570162X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016209787581391     Document Type: Review

References (48)

1. Andersen JL, Rouzic EL, Planelles V. HIV-1 Vpr: mechanisms of G2 arrest and apoptosis. Exp Mol Pathol 2008; 85: 2-10.
2. Bukrinsky MI, Haffar OK. HIV-1 nuclear import: in search of a leader. Front Biosci 1999; 4: 772-81.
3. Heinzinger NK, Bukrinsky MI, Haggerty SA, et al. The Vpr protein of human immunodeficiency virsu type 1 influences nuclear localization of viral nucleic acids in nondividing host cells. Proc Natl Acad Sci USA 1994; 91: 7311-5.
4. de Noronha CMC, Sherman MP, Lin HW, et al. Dynamic disruptions in nuclear envelope architecture and integrity induced by HIV-1 Vpr. Science 2001; 294: 1105-8.
5. Tachiwana H, Shimura M, Nakai-Murakami C, et al. HIV-1 Vpr induces DNA double-strand breaks. Cancer Res 2006; 66: 627-31.
6. Nakai-Murakami C, Shimura M, Kinomoto M, et al. HIV-1 Vpr induces ATM-dependent cellular signal with enhanced homologous recombination. Oncogene 2007; 26: 477-86.
7. Hoshino S, Sun B, Konishi M, et al. Vpr in plasma of HIV type 1- positive patients is correlated with the HIV type 1 RNA titers. AIDS Res Hum Retroviruses 2007; 23: 391-7.
8. Shimura M, Onozuka Y, Yamaguchi T, Hatake K, Takaku F, Ishizaka Y. Micronuclei formation with chromosome breaks and gene amplification caused by vpr, an accessory gene of human immunodeficiency virus. Cancer Res 1999; 59: 2259-64.
9. Shimura M, Tanaka Y, Nakamura S, et al. Microuclei formation and aneuploidy induced by Vpr, an accessory gene of human immunodeficiency virus type 1. FASEB J 1999; 13: 621-37.
10. Lau A, Swinbank KM, Ahmed PS, et al. Suppression of HIV-1 infection by a small molecule inhibitor of the ATM kinase. Nat Cell Biol 2005; 7: 493-500.
11. Daniel R, Kao G, Taganov K, et al. Evidence that the retroviral DNA integration process triggers an ATR-dependent DNA damage response. Proc Natl Acad Sci USA 2003; 100: 4778-83.
12. Ishizaka Y, Chernov MV, Burns CM, Stark GR. P53-dependent growth arrest of REF52 cells containing newly amplified DNA. Proc Natl Acad Sci USA 1995; 92: 3224-8.
13. Pierce AJ, Johnson RD, Thompson LH, Jasin M. XRCC3 promotes homology-directed repair of DNA damage in mammalian cells. Genes Dev 1999; 13: 2633-8.
14. Johnson RD, Liu N, Jasin M. Mammalian XRCC2 promotes the repair of DNA double-strand breaks by homologous recombination. Nature 1999; 401: 397-9.
15. Daniel R, Katz RA, Skalka AM. A role for DNA-PK in retroviral DNA integration. Science 1999; 284: 644-7.
16. Daniel R, Katz RA, Merkel G, et al. Wortmannin potentiates integrase- mediated killing of lymphocytes and reduces the efficiency of stable transduction by retroviruses. Mol Cell Biol 2001; 21: 1164-72.
17. Daniel R, Marusich E, Argyris E, Zhao RY, Skalka AM, Pomerantz RJ. Caffeine inhibits human immunodeficiency virus type 1 transduction of nondividing cells. J Virol 2005; 79: 2058-65.
18. Dehart JL, Andrersen JL, Zimmerman ES, et al. The ataxia telangiectasia- mutated and Rad3-related proteoin is dispensable for retroviral integration. J Virol 2005; 79: 1389-96.
19. Ariumi Y, Turelli P, Masutani M, Trono D. DNA damage sensors ATM, ATR, DNA-PKcs and PARP-1 are dispensable for human immunodeficiency virus type 1 integration. J Virol 2005; 79: 2973-8.
20. Smith JA, Wang FX, Zhang H, Wu KJ, Williams KJ, Daniel R. Evidence that the Nijmegen greakage syndrome protein, an early sensor of double strand DNA breaks (DSB), is involved in HIV-1 post-integration repair by recruiting the ataxia telangiectasia-mutated kinase in a process similar to, but distinct from, cellular DSB repair. Virol J 2008; 5: 11.
21. Daniel R, Ramcharan J, Rogakou E, et al. Histone H2AX is phosphorylated at sites of retroviral DNA integration but is dispensable for postintegration repair. J Biol Chem 2004; 279: 45810-4.
22. Suzuki Y, Misawa N, Sato C, et al. Quantitative analysis of human immunodeficiency virus type 1 DNA dynamics by real-time PCR: integration efficiency in stimulated and unstimulated peripheral blood mononuclear cells. Virus Genes 2003; 27: 177-88.
23. Zimmerman ES, Sherman MP, Blackett JL, et al. Human immunodeficiency virus type 1 Vpr induces DNA replication stress in vitro and in vivo. J Virol 2006; 80: 10407-18.
24. Lai M, Zimmerman ES, Planelles V, Chen J. Activation of the ATR pathway by human immunodeficiency virus type 1 Vpr involves its direct binding to chromatin in vivo. J Virol 2005; 79: 15443-51.
25. Bolton DL, Lenardo MJ. Vpr cytopathicity independent of G2/M cell cycle arrest in human immunodeficiency virus type 1 Vpr- and infected CD4+ T cells. J Virol 2007; 81: 8878-90.
26. Yuan H, Xie YM, Chen ISY. Depletion of Wee-1 kinase is necessary for both human immunodeficiency virus type 1 Vpr- and gamma irradiation-induced apoptosis. J Virol 2003; 77: 2063-70.
27. Zimmerman ES, Chen J, Andersen JL, et al. Human immunodeficiency virus type 1 Vpr-mediated G2 arrest requires Rad17 and Hus1 and Induces nuclear BRCA1 and γ-H2AX focus formation. Mol Cell Biol 2004; 24: 9286-94.
28. Roshal M, Kim B, Zhu Y, Nghiem P, Planelles V. Activation of the ATR-mediated DNA damage response by the HIV-1 viral protein R. J Biol Chem 2003; 278: 25879-86.
29. Yuan H, Kamata M, Xie YM, Chen ISY. Increased levels of Wee-1 kinase in G2 arrest are necessary for Vpr- and Gamma irradiation-induced G2 arrest. J Virol 2004; 78: 8183-90.
30. Jazayeri A, Falck J, Lukas C, et al. ATM- and cell cycle-dependent regulation of ATR in response to DNA double-strand breaks. Nat Cell Biol 2006; 8: 37-45.
31. Brown EJ, Baltimore D. Essential and dispensable roles of ATR in cell cycle arrest and genome maintenance. Genes Dev 2003; 17: 615-28.
32. Nyberg KA, Michelson RJ, Putnam CW, Weinert TA. Toward maintaining the genome: DNA damage and replication checkpoints. Annu Rev Genet 2002; 36: 617-56.
33. Dehart JL, Zimmerman ES, Ardon O, Monteiro-Filho CMR, Argañaraz ER, Planelles V. HIV-1 Vpr activates the G2 checkpoint through manipulation of the ubiquitin proteasome system. Virol J 2007; 4: 57.
34. Hrecka K, Gierszewska M, Srivastava S, et al. Lentiviral Vpr usurps Cul4-DDB1[VprBP] E3 ubiquitin ligase to modulate cell cycle. Proc Natl Acad Sci USA 2007; 104: 11778-83.
35. Le RE, Belaidouni N, Estrabaud E, et al. HIV1 Vpr arrests the cell cycle by recruiting DCAF1/VprBP, a receptor of the Cul4-DDB1 ubiquitin ligase. Cell Cycle 2007; 6: 182-8.
36. Schröfelbauer B, Hakata Y, Landau NR. HIV-1 Vpr function is mediated by interaction with the damage-specific DNA-binding protein DDB1. Proc Natl Acad Sci USA 2007; 104:4130-5.
37. Wen X, Duus KM, Friedrich TD, deNoronha CM. The HIV1 protein Vpr acts to promote G2 cell cycle arrest by engaging a DDB1 and Cullin4A-containing ubiquitin ligase complex using VprBP/DCAF1 as an adaptor. J Biol Chem 2007; 282: 27046-57.
38. Biggar RJ, Rosenberg PS, Coté T. Kaposi's sarcoma and non- Hodgkin's lymphoma following the diagnosis of AIDS. Int J Cancer 1996; 68: 754-7.
39. Straus DJ. HIV-associated lymphoma. Curr Oncol Rep 2001; 3: 260-5.
40. Mocroft A, Vella S, Benfield TL, et al. Changing patterns of mortality across Europe in patients infected with HIV-1. Lancet 1998; 352: 1725-30.
41. Strene JAC, Hernán MA, Ledergerber B, et al. Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study. Lancet 2005; 366: 378-84.
42. Biggar RJ, Chaturvedi AK, Goedert JJ, Engels EA. AIDS-related cancer and severity of immunosuppression in persons with AIDS. J Natl Cancer Inst 2007; 366: 378-84.
43. Engels EA, Pfeiffer RM, Goedert JJ, et al. Trends in cancer risk among people with AIDS in the United States 1980-2002. AIDS 2006; 20: 1645-54.
44. Engels EA, Biggar RJ, Hall HI, et al. Cancer risk in people infected with human immunodeficiency virus in the United States. Int J Cancer 2008; 123: 187-94.
45. Spano JP, Costagliola D, Katlama C, Mounier N, Oksenhendler E, Khayat D. AIDS-related malignancies: State of the Art and therapeutic challenges. J Clin Oncol 2008; 26: 1-9.
46. Shimura M, Tokunaga K, Konishi M, et al. Premature sister chromatid separation in HIV-1-infected peripheral blood lymphocytes. AIDS 2005; 19: 1434-8.
47. Siddiqui K, Valle LD, Morellet N, et al. Molecular mimicry in inducing DNA damage between HIV-1 Vpr and the anticancer agent, cisplatin. Oncogene 2008; 27: 32-43.
48. Van Maele B, Debyser Z. HIV-1 integration: an interplay between HIV-1 integrase, cellular and viral proteins. AIDS Rev 2005; 7: 26-43.